Cytokine Storm Syndromes in the ICU: HLH, MAS, and Emerging Therapies - A Critical Care Perspective

DR Neeraj Manikath , claude.ai

Abstract

Background: Cytokine storm syndromes represent a spectrum of life-threatening hyperinflammatory conditions characterized by excessive immune activation, multiorgan dysfunction, and high mortality rates. Hemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS) are the most recognized entities, though the COVID-19 pandemic has highlighted the broader clinical significance of cytokine storm phenomena in critical care.

Objective: This review provides a comprehensive analysis of cytokine storm syndromes encountered in the intensive care unit, focusing on pathophysiology, diagnostic challenges, and therapeutic approaches, with emphasis on emerging treatment modalities.

Methods: A systematic literature review was conducted using PubMed, EMBASE, and Cochrane databases from 2010-2024, focusing on adult critical care populations.

Results: Early recognition remains challenging due to overlapping clinical features with sepsis and other critical illnesses. Diagnostic criteria continue to evolve, with biomarker panels and genetic testing playing increasingly important roles. Treatment approaches have expanded beyond traditional immunosuppression to include targeted biologics and combination therapies.

Conclusions: A high index of suspicion, combined with systematic diagnostic approaches and prompt initiation of appropriate therapy, is essential for improving outcomes in these complex patients.

Keywords: cytokine storm, hemophagocytic lymphohistiocytosis, macrophage activation syndrome, critical care, immunomodulation

Introduction

Cytokine storm syndromes (CSS) represent a heterogeneous group of hyperinflammatory conditions that pose significant diagnostic and therapeutic challenges in the intensive care unit (ICU). These syndromes are characterized by excessive activation of the immune system, leading to uncontrolled release of pro-inflammatory cytokines, widespread tissue damage, and multiorgan failure¹.

The spectrum of CSS includes primary hemophagocytic lymphohistiocytosis (HLH), secondary HLH, macrophage activation syndrome (MAS), and other hyperinflammatory conditions that share similar pathophysiological mechanisms². The COVID-19 pandemic has brought renewed attention to these syndromes, highlighting their importance in critical care medicine³.

Understanding CSS is crucial for intensivists, as early recognition and appropriate treatment can significantly impact patient outcomes. However, the overlap in clinical presentation with common ICU conditions such as sepsis, acute respiratory distress syndrome (ARDS), and multiorgan dysfunction syndrome makes diagnosis challenging⁴.

Pathophysiology

Immune Dysregulation Mechanisms

The fundamental pathophysiology of CSS involves loss of immune homeostasis, leading to uncontrolled activation of macrophages, T-lymphocytes, and natural killer (NK) cells⁵. This dysregulation results from either:

Primary genetic defects in cytotoxic function (primary HLH)
Secondary triggers overwhelming normal regulatory mechanisms (secondary HLH/MAS)

The Cytokine Network Gone Awry

Key cytokines implicated in CSS include:

Interferon-γ (IFN-γ): Primary driver of macrophage activation
Tumor necrosis factor-α (TNF-α): Promotes systemic inflammation
Interleukin-1β (IL-1β): Mediates fever and acute-phase responses
Interleukin-6 (IL-6): Drives hepatic acute-phase protein synthesis
Interleukin-18 (IL-18): Enhances IFN-γ production and NK cell activation⁶

Vicious Cycle of Inflammation

The pathophysiology involves a self-perpetuating cycle:

Initial trigger activates immune cells
Excessive cytokine release occurs
Further immune cell activation ensues
Tissue damage and organ dysfunction develop
Additional inflammatory stimuli are released⁷

Clinical Pearl: The inability to "turn off" the inflammatory response distinguishes CSS from normal immune responses to infection or injury.

Clinical Presentation

Hemophagocytic Lymphohistiocytosis (HLH)

HLH typically presents with the classic pentad of:

Fever: Often high-grade and persistent
Splenomegaly: Present in 90% of cases
Cytopenias: Affecting ≥2 cell lines
Hypertriglyceridemia and/or hypofibrinogenemia
Hemophagocytosis: On bone marrow examination⁸

Macrophage Activation Syndrome (MAS)

MAS, commonly associated with rheumatologic conditions, presents similarly but may have:

More pronounced hepatomegaly
Elevated liver enzymes
Lower platelet counts
Higher ferritin levels (often >10,000 ng/mL)⁹

ICU-Specific Manifestations

In the critical care setting, CSS may present as:

Refractory shock requiring high-dose vasopressors
ARDS with severe hypoxemia
Acute kidney injury
Disseminated intravascular coagulation (DIC)
Central nervous system dysfunction¹⁰

Diagnostic Hack: Consider CSS in any ICU patient with unexplained fever, cytopenias, and extremely elevated ferritin (>3,000 ng/mL) who is not responding to standard treatments.

Diagnostic Approach

HLH-2004 Criteria

The widely used HLH-2004 criteria require 5 of 8 criteria:

Fever ≥38.5°C
Splenomegaly
Cytopenias (≥2 lineages)
Hypertriglyceridemia (≥265 mg/dL) or hypofibrinogenemia (≤1.5 g/L)
Hemophagocytosis in bone marrow, spleen, or lymph nodes
Low or absent NK cell activity
Ferritin ≥500 ng/mL
Elevated soluble CD25 (sIL2R) ≥2,400 U/mL¹¹

HScore Calculator

The HScore provides a probability-based diagnostic tool incorporating:

Clinical features (fever, organomegaly, immunosuppression)
Laboratory values (cytopenias, ferritin, triglycerides, AST, fibrinogen)
Bone marrow findings¹²

HScore Interpretation:

<90: Low probability
90-169: Intermediate probability
≥170: High probability

Novel Biomarkers

Emerging biomarkers showing promise include:

CXCL9: Elevated in HLH patients
CD163: Soluble marker of macrophage activation
IL-18: Significantly elevated in CSS
Neopterin: Marker of macrophage activation¹³

Laboratory Oyster: Extremely elevated ferritin (>10,000 ng/mL) in the absence of iron overload or liver disease should raise immediate suspicion for CSS.

Differential Diagnosis

Sepsis vs. CSS

Distinguishing CSS from sepsis remains challenging:

Feature	Sepsis	CSS
Fever pattern	Variable	Persistent high fever
White blood cell count	Often elevated	Usually decreased
Ferritin	Elevated (usually <3,000)	Markedly elevated (>3,000)
Triglycerides	Normal or mildly elevated	Significantly elevated
Response to antibiotics	Improvement expected	No improvement
Splenomegaly	Uncommon	Common

Other Conditions to Consider

Malignancy-associated HLH
Drug-induced hypersensitivity syndrome
Still's disease
Catastrophic antiphospholipid syndrome
Thrombotic thrombocytopenic purpura¹⁴

Treatment Strategies

First-Line Therapy: HLH-94 Protocol

The HLH-94 protocol remains the standard approach:

Dexamethasone: 10 mg/m² daily × 2 weeks, then taper
Etoposide: 150 mg/m² twice weekly × 8 weeks
Cyclosporine A: Target level 200-400 ng/mL¹⁵

Alternative Immunosuppressive Regimens

For patients unsuitable for etoposide:

High-dose corticosteroids alone
Anakinra (IL-1 receptor antagonist): 1-2 mg/kg daily
Tocilizumab (IL-6 receptor antagonist): 8 mg/kg monthly¹⁶

ICU-Specific Considerations

Hemodynamic Support

Vasopressor choice: Norepinephrine preferred over dopamine
Fluid management: Conservative approach due to capillary leak
Cardiac monitoring: Watch for cytokine-induced cardiomyopathy¹⁷

Respiratory Support

Mechanical ventilation: Lung-protective strategies
ECMO consideration: For refractory ARDS
Prone positioning: May be beneficial¹⁸

Renal Replacement Therapy

Continuous renal replacement therapy (CRRT) preferred
Plasmapheresis: Consider for removing inflammatory mediators
Cytokine removal: Specialized filters under investigation¹⁹

Emerging Therapies

Targeted Biologics

JAK Inhibitors

Ruxolitinib: JAK1/2 inhibitor showing promise
Mechanism: Blocks cytokine signaling pathways
Dosing: 5-10 mg twice daily²⁰

Anti-CD52 Antibodies

Alemtuzumab: Depletes T and B lymphocytes
Reserved for refractory cases
Risk of severe immunosuppression²¹

Complement Inhibition

Eculizumab: C5 complement inhibitor
Rationale: Complement activation in CSS
Limited clinical data available²²

Combination Approaches

Recent studies explore:

Triple therapy: Steroids + anakinra + tocilizumab
Sequential protocols: Early biologics followed by conventional therapy
Personalized approaches: Based on cytokine profiles²³

Cell-Based Therapies

Mesenchymal stem cells: Immunomodulatory properties
Regulatory T-cell infusions: Restore immune balance
NK cell therapies: Address primary defects²⁴

Treatment Pearl: Start immunosuppression early - delay in treatment initiation is associated with worse outcomes.

Special Populations

COVID-19-Associated CSS

The pandemic highlighted CSS in viral infections:

Pathophysiology: SARS-CoV-2 triggers hyperinflammation
Biomarkers: Elevated IL-6, ferritin, D-dimer
Treatment: Dexamethasone, tocilizumab, anakinra²⁵

Malignancy-Associated HLH

Most common secondary cause in adults
Lymphomas particularly associated
Treatment challenges: Balancing immunosuppression with cancer therapy
Prognosis: Generally poor without treating underlying malignancy²⁶

Post-Transplant CSS

Risk factors: EBV reactivation, graft-versus-host disease
Treatment modifications: Reduce immunosuppression paradoxically
Prognosis: Variable depending on timing and cause²⁷

Monitoring and Supportive Care

Laboratory Monitoring

Daily monitoring should include:

Complete blood count with differential
Comprehensive metabolic panel
Liver function tests
Coagulation studies
Ferritin, triglycerides, LDH
Fibrinogen²⁸

Response Assessment

Indicators of treatment response:

Clinical: Fever resolution, improved organ function
Laboratory: Normalizing cell counts, decreasing ferritin
Imaging: Resolution of organomegaly²⁹

Infection Prevention

Critical considerations:

Prophylaxis: PCP, fungal, viral
Surveillance: Regular cultures and imaging
Vaccination: Live vaccines contraindicated
Isolation precautions: As appropriate³⁰

Prognosis and Outcomes

Factors Affecting Prognosis

Poor prognostic factors:

Age >60 years
Underlying malignancy
CNS involvement
Delayed diagnosis and treatment
Multiorgan failure³¹

ICU-Specific Outcomes

Recent studies show:

ICU mortality: 40-60% in severe cases
Long-term outcomes: Survivors may have chronic sequelae
Functional recovery: Often incomplete³²

Prognostic Hack: Early normalization of ferritin and platelet count are strong predictors of favorable outcomes.

Future Directions

Precision Medicine Approaches

Genetic profiling: Identifying primary HLH variants
Cytokine profiling: Tailored therapeutic targeting
Biomarker development: Earlier diagnosis and monitoring³³

Novel Therapeutic Targets

Under investigation:

Inflammasome inhibitors
Autophagy modulators
Microbiome-based therapies
Extracellular vesicle therapeutics³⁴

Artificial Intelligence Applications

Diagnostic algorithms: Improving early recognition
Predictive models: Risk stratification
Treatment optimization: Personalized protocols³⁵

Clinical Pearls and Oysters

Pearls for the Intensivist

Think CSS early: In unexplained fever with cytopenias and hyperferritinemia
Don't wait for bone marrow: Start treatment based on clinical suspicion
Monitor for secondary infections: High index of suspicion needed
Consider malignancy workup: Especially in older adults
Involve hematology early: Specialized expertise crucial

Common Pitfalls (Oysters)

Attributing fever to infection only: Missing the hyperinflammatory component
Waiting for all criteria: Delaying treatment while collecting diagnostic evidence
Underestimating immunosuppression needs: Inadequate initial therapy
Overlooking genetic testing: Important for family counseling and treatment selection
Stopping treatment too early: Premature discontinuation leading to relapse

Conclusion

Cytokine storm syndromes represent complex, life-threatening conditions requiring prompt recognition and aggressive treatment in the ICU setting. The overlap with common critical care conditions makes diagnosis challenging, but a systematic approach using established criteria, novel biomarkers, and clinical suspicion can improve outcomes.

Treatment has evolved from purely cytotoxic approaches to targeted biological therapies, offering new hope for these critically ill patients. However, early intervention remains paramount, and the intensivist's role in recognizing and initiating appropriate therapy cannot be overstated.

Future advances in precision medicine, biomarker development, and novel therapeutics promise to further improve outcomes for patients with CSS. Until then, maintaining a high index of suspicion and collaborating closely with hematology-oncology colleagues remains essential for optimal patient care.

References

Crayne CB, Albeituni S, Nichols KE, Cron RQ. The immunology of macrophage activation syndrome. Front Immunol. 2019;10:119.
Ramos-Casals M, Brito-Zerón P, López-Guillermo A, Khamashta MA, Bosch X. Adult haemophagocytic syndrome. Lancet. 2014;383(9927):1503-1516.
Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033-1034.
Kyriazopoulou E, Leventogiannis K, Norrby-Teglund A, et al. Macrophage activation-like syndrome: an immunological entity associated with rapid progression to death in sepsis. BMC Med. 2017;15(1):172.
Janka GE, Lehmberg K. Hemophagocytic syndromes—an update. Blood Rev. 2014;28(4):135-142.
Shimizu M, Nakagishi Y, Yachie A. Distinct subsets of patients with systemic juvenile idiopathic arthritis based on their cytokine profiles. Cytokine. 2013;61(2):345-348.
Tisoncik JR, Korth MJ, Simmons CP, Farrar J, Martin TR, Katze MG. Into the eye of the cytokine storm. Microbiol Mol Biol Rev. 2012;76(1):16-32.
Henter JI, Horne A, Aricó M, et al. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48(2):124-131.
Ravelli A, Minoia F, Davì S, et al. 2016 Classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. Ann Rheum Dis. 2016;75(3):481-489.
La Rosée P, Horne A, Hines M, et al. Recommendations for the management of hemophagocytic lymphohistiocytosis in adults. Blood. 2019;133(23):2465-2477.
Henter JI, Horne A, Aricó M, et al. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48(2):124-131.
Fardet L, Galicier L, Lambotte O, et al. Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome. Arthritis Rheumatol. 2014;66(9):2613-2620.
Allen CE, Yu X, Kozinetz CA, McClain KL. Highly elevated ferritin levels and the diagnosis of hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2008;50(6):1227-1235.
Morimoto A, Nakazawa Y, Ishii E. Hemophagocytic lymphohistiocytosis: Pathogenesis, diagnosis, and management. Pediatr Int. 2016;58(9):817-825.
Henter JI, Samuelsson-Horne A, Aricò M, et al. Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation. Blood. 2002;100(7):2367-2373.
Schulert GS, Grom AA. Pathogenesis of macrophage activation syndrome and potential for cytokine-directed therapies. Annu Rev Med. 2015;66:145-159.
Lachmann G, Spies C, Schenk T, et al. Hemophagocytic lymphohistiocytosis: potentially underdiagnosed in intensive care units. Shock. 2018;50(6):606-617.
Buyse S, Teixeira L, Galicier L, et al. Critical care management of patients with hemophagocytic lymphohistiocytosis. Intensive Care Med. 2010;36(10):1695-1702.
Stahl M, Schlüter F, Karpova D, et al. Hemophagocytic lymphohistiocytosis in the intensive care unit: Clinical manifestations, outcomes and novel treatment approaches. Crit Care. 2020;24(1):407.
Ahmed A, Merrill SA, Alsawah F, et al. Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot trial. Lancet Haematol. 2019;6(12):e630-e637.
Marsh RA, Allen CE, McClain KL, et al. Salvage therapy of refractory hemophagocytic lymphohistiocytosis with alemtuzumab. Pediatr Blood Cancer. 2013;60(1):101-109.
Valga F, Vázquez-Martul E, Rodríguez-Suárez C, et al. Hemophagocytic syndrome secondary to visceral leishmaniasis in a kidney transplant patient: successful treatment with liposomal amphotericin B. Nefrologia. 2012;32(5):699-700.
Khadka S, Grobman WA, Kahn A, et al. Treatment of secondary hemophagocytic lymphohistiocytosis in adults: A systematic review. J Crit Care. 2021;61:209-218.
Olin RL, Nichols KE, Naghashpour M, et al. Successful use of the anti-CD25 antibody daclizumab in an adult patient with hemophagocytic lymphohistiocytosis. Am J Hematol. 2008;83(9):747-749.
England JT, Abdulla A, Biggs CM, et al. Weathering the COVID-19 storm: Lessons from hematologic cytokine syndromes. Blood Rev. 2021;45:100707.
Ramos-Casals M, Brito-Zerón P, López-Guillermo A, Khamashta MA, Bosch X. Adult haemophagocytic syndrome. Lancet. 2014;383(9927):1503-1516.
Hügle B, Widmer N, von Vigier RO, et al. A case of post-transplant lymphoproliferative disorder mimicking hemophagocytic syndrome. Pediatr Transplant. 2010;14(8):E132-E135.
Jordan MB, Allen CE, Weitzman S, Filipovich AH, McClain KL. How I treat hemophagocytic lymphohistiocytosis. Blood. 2011;118(15):4041-4052.
Lehmberg K, Pink I, Eulenburg C, Beutel K, Maul-Pavicic A, Janka G. Differentiating macrophage activation syndrome in systemic juvenile idiopathic arthritis from other forms of hemophagocytic lymphohistiocytosis. J Pediatr. 2013;162(6):1245-1251.
Henter JI, Chow CB, Leung CW, Lau YL. Cytotoxic therapy for severe swine flu H1N1-associated hemophagocytic lymphohistiocytosis. Leukemia. 2010;24(12):2151-2153.
Rivière S, Galicier L, Coppo P, et al. Reactive hemophagocytic syndrome in adults: a retrospective analysis of 162 patients. Am J Med. 2014;127(11):1118-1125.
Parikh SA, Kapoor P, Letendre L, Kumar S, Wolanskyj AP. Prognostic factors and outcomes of adults with hemophagocytic lymphohistiocytosis. Mayo Clin Proc. 2014;89(4):484-492.
Zhang K, Jordan MB, Marsh RA, et al. Hypomorphic mutations in PRF1, MUNC13-4, and STXBP2 are associated with adult-onset familial HLH. Blood. 2011;118(22):5794-5798.
Canna SW, Marsh RA. Pediatric hemophagocytic lymphohistiocytosis. Blood. 2020;135(16):1332-1343.
Lehmberg K, Ehl S. Diagnostic evaluation of patients with suspected haemophagocytic lymphohistiocytosis. Br J Haematol. 2013;160(3):275-287.

Saturday, September 20, 2025

Cytokine Storm Syndromes -Emerging Therapies